TSX:BCT - Post Discussion
Post by
LondonInvest on Mar 17, 2022 3:40pm
Keytruda Lung Cancer Reduction, Good News for BCTX Study
Merck just released results for their Keytruda Lung cancer study and it showed a 24% reduction in disease recurrence or death. Good news for Briacell as this is one of the new therapeutic targets they are going after in 2H2022. Things continue to line-up for Briacell. Promising indicator for their technology working too.
https://www.cnbc.com/2022/03/17/mercks-keytruda-reduced-risk-of-recurrence-or-death-in-early-lung-cancer-patients-by-24percent.html \
Be the first to comment on this post